GSK Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Aug 1, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Aug 1, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, stock-transaction
TL;DR
GSK is buying back its own stock via Merrill Lynch.
AI Summary
GSK plc announced on August 1, 2025, that it purchased a certain number of its own ordinary shares through its corporate stockbroker, Merrill Lynch International. The filing does not specify the exact number of shares or the total dollar amount of the transaction.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This is a routine disclosure of share repurchases, which is common for many public companies.
Key Players & Entities
- GSK plc (company) — Registrant
- Merrill Lynch International (company) — Corporate stockbroker
- 001-15170 (other) — SEC File Number
FAQ
What was the total number of GSK ordinary shares purchased?
The filing states that a 'certain number' of shares were purchased but does not specify the exact quantity.
What was the total dollar amount spent on the share repurchase?
The filing does not disclose the total dollar amount of the transaction.
On what date did GSK announce this transaction?
GSK announced the transaction on August 1, 2025.
Who acted as GSK's corporate stockbroker for this transaction?
Merrill Lynch International acted as GSK's corporate stockbroker.
What is the par value of GSK's ordinary shares?
The par value of GSK's ordinary shares is 31¼ pence each.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on August 1, 2025 regarding GSK plc (GLAXF).